Home  |  Contact

UniProtKB/Swiss-Prot P11712: Variant p.Ile434Phe

Cytochrome P450 2C9
Gene: CYP2C9
Variant information

Variant position:  434
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Isoleucine (I) to Phenylalanine (F) at position 434 (I434F, p.Ile434Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (I) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In allele CYP2C9*59; produces warfarin hypersensitivity; increases affinity but highly decreases enzymatic activity for tolbutamide; no effect on affinity but decreases enzymatic activity for diclofenac; decreases affinity and highly decreases enzymatic activity for losartan.
Any additional useful information about the variant.

Sequence information

Variant position:  434
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  490
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 490 Cytochrome P450 2C9
Metal binding 435 – 435 Iron (heme axial ligand)
Alternative sequence 163 – 490 Missing. In isoform 2.

Literature citations

Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59.
Dai D.P.; Wang S.H.; Li C.B.; Geng P.W.; Cai J.; Wang H.; Hu G.X.; Cai J.P.;
Drug Metab. Dispos. 43:1246-1249(2015)

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.